Prescription Drug Inflation Slowing, CMS Studies Show

Prescription Drug Inflation Slowing, CMS Studies Show
Published Online: Monday, August 1, 2005

The rising cost of prescription drug therapy—a key factor in overall health care inflation for the past decade—has begun to moderate.

New figures issued by the government's Centers for Medicare and Medicaid Services (CMS) indicate that total US spending on prescription medicines rose 10.7% in 2003, a significantly slower rate of increase than the 14.9% jump that occurred in 2002.

Health care analysts contend that this moderating trend has continued into 2005, thanks to a variety of factors including increased consumer acceptance of generic drugs, cost-containment efforts by pharmacy benefit managers, and the withdrawal of several high-priced prescription painkillers such as Vioxx and Bextra.

Mr. Rankin is a freelance medical writer.

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues